Oracle today announced the creation of the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs. The Institute is focused on research that will accelerate IT innovation to advance personalized medicine and the delivery of safe and effective treatments and health care services to patients around the globe.
OHSI will work in tandem with academic research centers, focusing on a targeted set of research areas fundamental to the R&D and health care delivery challenges facing health sciences organizations today. OHSI’s research priorities currently include: artificial intelligence and semantic technology; genomic, genetic and phenotypic data analysis; data mining to support optimization of clinical trials; and predictive algorithms and other technology to advance patient safety and provide advanced decision support at the point of care.
“IT innovation is essential to accelerating the discovery, development and delivery of next-generation treatments, therapies and health care service innovations,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “Oracle created the Oracle Health Sciences Institute, in partnership with Sun Labs, to advance this objective. By combining Oracle and Sun Labs’ scientific talent and resources with collaborators worldwide, OHSI is positioned to help design IT innovations that will aid in improving patient care around the world.”
Academic institutions interested in collaborating with OHSI in these focus areas should contact OHSI representatives at OHSInstitute_ww@oracle.com for additional information.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.